SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs latest Phase 3 breast-cancer results are drawing attention: the drug met its primary endpoint but delivered only a modest benefit versus chemotherapy, with higher lung-inflammation rates. Traders are debating whether this and an earlier cancer-trial setback signal broader pipeline weakness or are outweighed by other oncology programs and an upcoming pipeline update.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios quarterly results beat expectations and lifted its full-year outlook, but a softer next-quarter organic growth forecast signaled deceleration and drove a sharp selloff. Traders are debating whether slowing messaging growth and weaker customer expansion outweigh the strong results, while some see the pullback as a potential bounce opportunity.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Traders are focused on whether Q3 results will show that oral Wegovy demand and international expansion can offset concerns about Eli Lillys competitive lead in GLP-1 drugs. The community is divided: some see the pill rollout and low valuation as recovery potential, while others remain cautious about Novos execution, management and pipeline; the Hengrui licensing deal also drew debate as a longer-term pipeline move.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

SCHD is drawing attention as investors discuss its role as a defensive, dividend-focused alternative to volatile technology and growth stocks, amid shifting market leadership. Traders are divided between accumulating it for income and stability and citing rising Treasury yields or renewed tech strength as reasons for its recent weakness.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

A sharp selloff and persistent volatility dominate discussion, with traders pointing to broader weakness in miners and uncertainty over Sangdongs production ramp and near-term cash flows. Some remain bullish on tungsten-market fundamentals and the mines first shipment, while others say the investor-day discussion offered little new detail and are concerned about execution.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens run to recent highs has traders focused on its upcoming quarterly results, with options activity drawing attention; some view put buying as protection ahead of the report rather than a bearish bet. Optimism around the companys recent positive IMDELLTRA lung-cancer trial results also supports the pipeline discussion.

Crown Castle, Inc. engages in the business of owning, operating, and leasing shared communications infrastructure. It operates through the following segments: Towers, Fiber, and Other. The Towers segment focuses on providing coverage and capacity for wireless carrier network deployments. The Fiber segment includes communications infrastructure offerings of small cells and fiber solutions. The Other segment is involved in corporate assets such as cash and cash equivalents. The company was founded by Ted B. Miller Jr. and Edward C. Hutcheson Jr. in 1994 and is headquartered in Houston, TX.

Crown Castle Inc

Crown Castle International Corp

Reports that SpaceX is in talks to access at least 80,000 U.S. cell sites, including Crown Castles towers, have focused attention on the prospect of a major new leasing customer. Traders see potential tower revenue upside, while skeptics note that no agreement is signed and question whether SpaceXs wireless plans will translate into meaningful demand.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royces sharp pullback is prompting debate over whether oil and jet-fuel concerns, broader market weakness, and aerospace-sector signals are driving the selling despite no widely cited deterioration in company fundamentals. Traders also point to the UK government-backed narrowbody engine development programme as a long-term positive, though some are frustrated that it has not offset the recent weakness.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs quarterly report and weaker-than-expected outlook for holiday-quarter bookings, alongside a daily-user miss, triggered a sharp selloff despite some headline results beating estimates. Traders are split between viewing the drop as a buying opportunity near support and warning that slowing engagement and bookings point to weaker growth.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins sharp, sustained selloff is the dominant topic, with traders debating whether broader tech weakness, concerns about ad-market growth and analyst downgrades are weighing on the stock ahead of earnings. Bulls view the decline as disconnected from the companys growth and profitability, while bears worry about further downside and a weak earnings reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics (CGTX) delivered earnings and revenue surprises of +33.33% and -120.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%

Equity

The company reported that the U.S. Food and Drug Administration aligned with the company on several key aspects of the Phase 3 study, which is expected to begin in mid-2027.

Cognition Therapeutics (CGTX) to Release Earnings on Wednesday

Cognition Therapeutics (NASDAQ:CGTX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-cognition-therapeutics-inc-stock...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of "Moderate Buy" by Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the four analysts that are covering the firm, MarketBeat reports. One research...

Insider Buying: Cognition Therapeutics (NASDAQ:CGTX) CEO Acquires 9,175 Shares of Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the company's stock in a transaction dated Thursday, April 16th. The shares were acquired at an...

John Brendan Doyle Purchases 10,000 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CFO John Brendan Doyle bought 10,000 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average cost of $1.13 per share, with a total value of $11,300.00. Following the completion of...

Lisa Ricciardi Acquires 9,175 Shares of Cognition Therapeutics (NASDAQ:CGTX) Stock

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) CEO Lisa Ricciardi acquired 9,175 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $1.10 per share, with a total value of $10,092.50. Following the...

Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans

Cognition Therapeutics (NASDAQ:CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage...

Q1 Earnings Forecast for CGTX Issued By HC Wainwright

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Cognition Therapeutics in a research report issued on Friday...

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of "Moderate Buy" by Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the four research firms that are covering the stock, MarketBeat reports. One...

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

Cognition Therapeutics Inc

Bearish Sentiment

<ul class="summary-bullets"><li>The trial will evaluate once-daily 100 mg oral Zervimesine against a placebo in DLB patients experiencing hallucinations and delusions over a nine-month period.</li><li>The company plans to present additional Phase 2 data at the Alzheimer’s Association International Conference in July.</li><li>CGTX stock recorded its biggest single-day drop in nearly two years.</li></ul>Shares of Cognition Therapeutics (CGTX) tanked more than 33% on Wednesday, clocking their biggest single-day slide in nearly two years, as investors raised questions about the path forward for the company’s Phase 3 program targeting dementia with Lewy bodies (DLB) psychosis following a fresh regulatory update.<h2 class="st-heading-2">FDA Alignment On Phase 3 Trial</h2>The company reported that the U.S. Food and Drug Administration (FDA) provided favorable feedback on its planned Phase 3 program for Zervimesine in DLB psychosis. The agency aligned with the company on several key aspects of the pivotal study, which is expected to begin in mid-2027.The trial will evaluate once-daily 100 mg oral Zervimesine against a placebo in DLB patients experiencing hallucinations and delusions over a nine-month period.The Phase 3 trial is based on positive results from Cognition’s Phase 2 Shimmer study in patients with mild-to-moderate DLB, where the drug improved psychosis symptoms compared with placebo.A recent analysis showed the drug slowed the progression of hallucinations and delusions by 89%. The company plans to present additional Phase 2 data on these benefits at the Alzheimer’s Association International Conference (AAIC) in July.<h2 class="st-heading-2">What Are CGTX Traders Saying?</h2>While retail sentiment surrounding <a href="https://stocktwits.com/symbol/CGTX">CGTX</a> remained in the ‘extremely bullish’ territory over the past 24 hours, chatter focused on potential dilution to run the program.One user believes the “disappointment is the timeline” as the approved trial will not start for an entire year.<stembedurl>https://stocktwits.com/1rb/message/657295519</stembedurl>Another user said “pretty much zero catalyst the rest of the year,” while also expressing dilution concerns if the company fails to secure funding.<stembedurl>https://stocktwits.com/FitzCatalyst/message/657297638</stembedurl>As of March 31, 2026, the company had around $31.2 million in cash, cash equivalents, and restricted cash, along with $25.6 million in grants. The company believes its resources are sufficient to fund operations and capital spending through the second quarter of 2027.CGTX shares have declined more than 22% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/inmd-stock-gains-on-takeover-offer/cZKyQVJR7fZ">INMD Stock Heads For Best Day In Nearly Six Months – How Does The Latest Takeover Proposal Compare To Steel Partners’ Offer?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.6982
Prev Close	$0.7394
Open	$0.7216
Dividend Yield	0.00%
50-Day Moving Average	$0.9136
Beta	1.85
Avg. Volume	406,528.02
PE Ratio	-3.57

52-Week High	$1.83
52-Week Low	$0.5501
Market Capitalization	$66.39M
EPS (Annual)	-$0.3228
Price to Book	2.01
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGTX Fundamentals